Poultry Pharmaceuticals Market – By Species, By Product, By Disease Type, By Route of Administration, By End Use – Global Forecast, 2025 – 2034

Poultry Pharmaceuticals Market Size

The global poultry pharmaceuticals market was valued at USD 6.6 billion in 2024. The market is expected to grow from USD 7 billion in 2025 to USD 13.2 billion in 2034, at a CAGR of 7.3% during the forecast period. The growth of the poultry pharmaceutical market is primarily driven by rising global poultry consumption, as consumers increasingly shift toward affordable, protein-rich food sources such as chicken and eggs.

At the same time, heightened concerns over antibiotic resistance have prompted stricter regulations on antibiotic usage in poultry, further supporting the adoption of alternative health solutions and driving market expansion. Poultry pharmaceuticals comprise a diverse range of products, including vaccines, antibiotics, anticoccidials, probiotics, vitamins, and feed additives, designed to prevent, treat, or manage diseases in poultry species such as chickens, turkeys, ducks, and other domesticated birds.
 

Key market players such as Zoetis, Merck Animal Health, Elanco, Ceva Sante Animale, Boehringer Ingelheim, and Phibro Animal Health maintain a stronghold on the industry through strategic initiatives such as expanding vaccine portfolios, investing in R&D, and strengthening global distribution networks.
 

The market observed steady growth, increasing from USD 5.5 billion in 2021 to USD 6.2 billion in 2023. This upward trend is fueled by rising demand for poultry-derived products and an increasing frequency of disease outbreaks in commercial poultry operations. There is a growing emphasis on biosecurity, preventive healthcare, and the use of non-antibiotic solutions, such as vaccines and probiotics, to maintain flock health. Also, the shift toward antibiotic-free and organic poultry farming is accelerating demand for sustainable and natural therapeutic alternatives. Consequently, biologics and advanced vaccine technologies have emerged as the fastest-growing segments, significantly reshaping the competitive landscape.
 

Pharmaceutical companies are ramping up innovation by investing in next-generation vaccine technologies, including recombinant, vector-based, and mRNA-based formulations. These novel solutions offer improved efficacy, safety, and ease of administration, critical factors in large-scale poultry operations. For example, in June 2025, Boehringer Ingelheim introduced a next-generation, single-dose, three-in-one poultry vaccine in India, offering broad protection against three prevalent poultry diseases.
 

Growing R&D efforts are focused on developing next-gen therapeutics with enhanced safety profiles and efficacy, which is expected to drive the future adoption of poultry medications. For instance, in March 2025, Merck Animal Health announced European Commission approval for Nobilis Multriva REOm, a vaccine for chickens aimed at reducing avian reovirus (ARV) infections in progeny through passive immunization. Thus, availability of products along with regulatory pressures and advancements in veterinary technology, is fostering a market shift from reactive to preventive healthcare approaches.
 

Moreover, emerging markets such as Asia-Pacific and Latin America are witnessing increased investment in veterinary infrastructure and pharmaceutical accessibility, contributing further to market momentum.
 

Poultry Pharmaceuticals Market Trends

• The market is witnessing a transition from therapeutic treatment to preventive healthcare, driven by rising incidences of infectious diseases in commercial poultry operations. This shift is increasing demand for vaccines, probiotics, and medicated feed additives.
   
• Heightened concerns around antimicrobial resistance and consumer preference for clean-label meat are pushing producers toward antibiotic-free production. This trend is fueling the adoption of phytogenics, enzymes, organic acids, and natural alternatives.
   
• Leading players are forming strategic alliances to enhance their offerings. In April 2024, Merck Animal Health partnered with Cambridge Technologies to market customized autogenous poultry vaccines in the U.S., combining Merck’s distribution scale with Cambridge’s production capabilities. Similarly, personalized, farm-specific solutions, such as autogenous vaccines, are gaining traction for their targeted efficacy and role in reducing blanket medication use.
   
• Advancements in recombinant DNA, vector-based, and thermostable vaccines are enabling more targeted, effective, and stable disease prevention. For instance, Boehringer Ingelheim’s thermostable vaccines support distribution in tropical markets with limited cold-chain infrastructure.
   
• Also, the integration of IoT, AI, and sensor technologies in poultry farms enables real-time health monitoring, allowing for timely and precise pharmaceutical interventions, reducing overuse of medications, and improving flock outcomes.
   
• Asia-Pacific, Latin America, and Sub-Saharan Africa are witnessing rapid poultry industry expansion, supported by rising protein demand, population growth, and improving veterinary infrastructure. These regions present significant growth opportunities for pharmaceutical manufacturers.
   
• Government-backed health programs and international awareness campaigns are promoting preventive care in poultry health. For example, In January 2024, Brazil and Mexico implemented a regionalization initiative to manage avian influenza outbreaks more effectively and maintain poultry trade flows. Under this plan, export restrictions are applied only to affected municipalities, rather than entire states, helping to safeguard commerce in unaffected areas. This reflects industry and government alignment on biosecurity, allowing poultry producers to maintain operations even amid localized disease events.
   

Poultry Pharmaceuticals Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

 In 2021, the global market was valued at USD 5.5 billion. The following year, it saw a slight increase to USD 5.8 billion, and by 2023, the market further climbed to USD 6.2 billion.
 

Based on species, the global market is divided into chicken, turkey, ducks and other species. The chicken species segment accounted for 72.5% of the market in 2024 due to the high prevalence of infectious diseases, well-established vaccination protocols, and the rapid expansion of commercial broiler and layer farming. The segment is expected to exceed USD 9.4 billion by 2034, growing at a CAGR of 7.2% during the forecast period.
 

• Chickens remain the primary focus of poultry pharmaceutical interventions due to their dominant share in global poultry production. According to the Food and Agriculture Organization (FAO, 2023), chickens represent over 90% of the global poultry population, with more than 33 billion birds raised annually, underscoring the critical need for preventive health solutions.
   
• The high disease burden in chickens, caused by conditions such as Newcastle disease, infectious bursal disease (IBD), Marek’s disease, and coccidiosis, further amplifies demand for vaccines and therapeutics. As highlighted by the World Organization for Animal Health (WOAH), Newcastle disease alone can cause up to 100% mortality in unvaccinated flocks, reinforcing the necessity for robust vaccination strategies.
   
• Moreover, the rise of intensive poultry farming, particularly in developing economies, has increased the adoption of structured vaccination programs for both broilers and layers to optimize flock health, reduce mortality, and sustain productivity.
   
• In contrast, the duck segment is emerging as the fastest-growing category, projected to expand at a CAGR of 7.8% through 2034. Growth in this segment is driven by the availability of targeted duck vaccines and the increasing incidence of diseases such as duck viral enteritis (DVE), duck hepatitis, and avian influenza, prompting greater use of pharmaceutical interventions in duck production systems.
   

Based on the product, the poultry pharmaceuticals market is segmented into biologics, pharmaceuticals and medicated feed additives. The pharmaceuticals segment accounted for the highest market share of 48.1% in 2024. This dominance is attributed to the ease of administration, long-term safety, and the growing preference for preventive health solutions over reactive treatments. The pharmaceuticals segment is further sub-divided into parasiticides, anti-infectives, anti-inflammatory and analgesics, and other pharmaceuticals.
 

• A global shift toward antimicrobial stewardship is reinforcing demand for alternatives to traditional antibiotics. With increasing regulations and restrictions on antibiotic use in many regions, farmers are increasingly turning to probiotic and prebiotic-based pharmaceutical solutions to maintain flock health and mitigate disease risk.
   
• Further accelerating market growth are government and NGO-led livestock health initiatives, particularly in emerging markets. These programs, often aimed at disease eradication and improving food security, are driving the adoption of poultry pharmaceutical products, especially among small and mid-sized farm operators.
   
• While pharmaceuticals currently lead the market, the biologics segment is expected to expand at a faster rate, driven by recurring outbreaks of viral and bacterial infections. Biologic vaccines offer broad-spectrum protection, rapid immunization, and herd-level efficacy, making them a vital tool in modern poultry disease management.
   
• Technological advancements are also reshaping vaccine delivery. Automated systems such as in-ovo vaccination allow biologics to be administered at the hatchery stage, improving uniformity, reducing labor dependency, and enhancing scalability, especially in large-scale commercial poultry operations.   
   

Based on disease type, the poultry pharmaceuticals market is classified into Newcastle disease, infectious bronchitis, infectious bursal disease (IBD), coccidiosis, salmonella, Marek's disease and other disease types. The Newcastle disease segment dominated the market in 2024 and is growing with a CAGR of 7.6% during the forecast period.
 

• Newcastle disease remains the leading disease segment in the market, gaining significant traction due to its high contagion, mortality rate, and severe economic impact. The virus causes respiratory, neurological, and gastrointestinal symptoms, making vaccination a critical component of poultry health management, particularly in commercial operations.
   
• Rising demand for thermostable and easy-to-administer vaccines is accelerating adoption in rural and resource-limited regions, where cold-chain logistics are often challenging. The surge in poultry production across countries like India, China, Nigeria, and Ethiopia further drives demand for routine Newcastle Disease (ND) vaccination to prevent large-scale losses.
   
• Infectious bronchitis (IB) is the second-largest disease segment, accounting for 18.5% of the market in 2024. The IB virus frequently mutates, producing diverse regional genotypes that necessitate continuous and customized immunization programs. According to the Journal of Veterinary Research (2023), over 50 genotypes of IBV have been identified globally, underlining the need for adaptive and broad-spectrum vaccines.
   
• Though smaller in size, the Marek’s disease segment is projected to grow at a CAGR of 6.4%, supported by the emergence of more virulent strains and technological progress in vaccine development. Rispens-based vaccines, for instance, offer over 90% protection against very virulent Marek’s Disease Virus (MDV) strains, as reported by Ceva and Poultry Science Journal. Thus, enhancing their market potential.
   

Based on route of administration, the poultry pharmaceuticals market is bifurcated into oral, injectable, topical and other routes of administration. The oral segment was anticipated to be worth USD 4.1 billion in 2024 and is expected to grow at 7.3% CAGR during the forecast period.
 

• Oral administration is favored for its efficiency and scalability, allowing mass immunization of large flocks with minimal handling, making it ideal for commercial poultry operations.
   
• Oral vaccines also offer enhanced mucosal and systemic immunity by targeting gut-associated lymphoid tissue (GALT), a key defense against enteric and respiratory pathogens. According to an NCBI study, oral vaccines have demonstrated strong efficacy in managing diseases like Newcastle Disease.
   
• Technological advancements in thermostable oral vaccines have further expanded their application, particularly in hot climates and remote areas where maintaining cold chain logistics is challenging.
   
• Additionally, oral formulations support broader accessibility in low-infrastructure settings, providing an effective solution for smallholder and backyard poultry farms, where veterinary access is limited and ease of administration is critical.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the poultry pharmaceuticals market is classified into veterinary hospitals and clinics, poultry farms, retail veterinary pharmacies, and other end users. The poultry farms segment dominated the market in 2024 and is expected to reach 7.2 billion within the forecast period. 
 

• The expansion of commercial poultry farming to meet rising global demand for affordable animal protein is significantly driving the need for effective vaccination and disease management solutions. According to the World Organization for Animal Health (WOAH, 2023), global poultry meat consumption is expected to hit 150 million tons by 2032, accounting for 41% of total meat intake.
   
• Increasing access to veterinary services, mobile clinics, and farmer training programs has improved disease awareness at the farm level. This enhanced understanding of preventive care and vaccination protocols is contributing to higher uptake of poultry pharmaceutical products.
   
• Additionally, to meet export regulations and international biosecurity standards, commercial poultry farms are adopting certified vaccination programs. Countries like Thailand and Brazil now vaccinate over 90% of their poultry flocks against key diseases, reinforcing the need for consistent pharmaceutical interventions in globally integrated poultry production systems. 

Looking for region specific data?

Download Free PDF

The North America poultry pharmaceuticals market dominated the global market with a market share of 38.3% in 2024.
 

The U.S. market was valued at USD 1.9 billion and USD 2 billion in 2021 and 2022, respectively. The market size reached USD 2.3 billion in 2024, growing from USD 2.1 billion in 2023.
 

• The regional growth is owing to high poultry meat demand and the prevalence of industrial-scale farming, which increases disease vulnerability. According to the USDA, the U.S. produced over 52 billion pounds of broiler meat in 2023, making vaccination essential for productivity and food safety.
   
• Regulatory authorities in the U.S. and Canada enforce stringent biosecurity and vaccination mandates, thereby reinforcing preventive pharmaceutical adoption.
   
• Recurring outbreaks of Newcastle disease and HPAI continue to escalate vaccine demand. Notably, HPAI impacted over 58 million birds in the U.S., prompting nationwide immunization strategies. These initiatives have been strongly supported by USDA-APHIS through comprehensive disease surveillance and response programs, reinforcing the resilience of the poultry sector.
   
• Programs like the National Poultry Improvement Plan (NPIP) promote standardized vaccination protocols and biosecurity compliance, driving consistent pharmaceutical uptake.
   

Europe poultry pharmaceuticals market accounted for USD 1.6 billion in 2024 and is anticipated to show considerable growth over the forecast period.
 

• Europe plays a critical role in the global market, supported by its advanced healthcare infrastructure and an emphasis on animal welfare.
   
• Poland and Romania are witnessing rapid growth in commercial poultry production, with Poland leading as the EU's largest poultry meat producer.
   
• Also, in collaboration with academic institutions and EU-funded research projects, Germany is pioneering digital poultry health platforms. These integrate sensor-based data collection, real-time vaccine efficacy tracking, and AI-driven outbreak modeling, allowing producers to optimize pharmaceutical usage and reduce reliance on broad-spectrum antimicrobial
   
• The region is a hub for veterinary biotech innovation. Leading players are developing advanced poultry vaccine such as recombinant and vector-based solutions to combat evolving disease strains Germany dominates the European poultry pharmaceuticals market, showcasing strong growth potential.
   
• Germany dominates the European market, driven by stringent compliance with EU Animal Health Law (Regulation 2016/429). This law requires comprehensive disease surveillance, mandatory vaccination schedules, and biosecurity planning across poultry production facilities. Compliance is particularly rigorous in breeder and hatchery operations, where early immunization is essential to maintaining animal welfare and trade certifications.
   
• As one of the EU’s top poultry meat exporters, Germany shipped over 380,000 metric tons of poultry meat in 2023 to countries across Europe, the Middle East, and Asia. This necessitates strict adherence to international veterinary certifications and residue-free pharmaceutical usage, propelling demand for regulated, traceable poultry pharmaceuticals.
   
• Germany is home to leading global animal health companies such as Boehringer Ingelheim, which operates advanced R&D and manufacturing facilities for avian vaccines.
   

The Asia Pacific poultry pharmaceuticals market is anticipated to grow at the highest CAGR of 7.9% during the analysis timeframe.
 

• The Asia Pacific is projected to be the fastest-growing region in the global market, driven by demographic expansion, increasing urbanization, and rising demand for high-quality animal protein.
   
• Rapid intensification of poultry farming across developing economies is creating unprecedented demand for preventive and therapeutic health solutions.
   
• Frequent avian influenza (H5N1) and Newcastle Disease outbreaks have plagued the region. These diseases not only cause high mortality but also affect cross-border trade. In response, governments are deploying mass vaccination programs and tightening import/export regulations. 
   
• Public-private partnerships (PPPs) are also helping disseminate vaccines and pharmaceuticals to smallholder farms, especially those traditionally underserved by commercial distribution networks.
   

China poultry pharmaceuticals market is estimated to grow with a significant CAGR in the Asia Pacific market.
 

• The country’s vast geographic and climatic diversity contributes to region-specific disease burdens such as duck plague in the humid southern provinces and recurring avian influenza outbreaks in the colder northern regions, necessitating localized, targeted vaccination strategies.
   
• To address these challenges, the Chinese government, through the Ministry of Agriculture and Rural Affairs (MARA), has implemented robust disease control initiatives, including mandatory immunization programs, enhanced traceability systems, and stricter regulations on antibiotic use.
   
• Concurrently, rapid modernization in China's poultry sector has accelerated the adoption of IoT-enabled monitoring, automated vaccine delivery systems, and data-driven disease management, particularly in large-scale commercial farms.
   
• These advancements not only improve pharmaceutical efficiency and reduce reliance on antibiotics but also align with evolving consumer expectations for traceable, residue-free poultry products. The post-COVID era has amplified these demands, especially among urban consumers, prompting farms to adopt higher biosecurity and animal health standards.
   

Brazil leads the Latin American poultry pharmaceuticals market, exhibiting remarkable growth during the analysis period.
 

• National programs such as the PNFA (National Poultry Health Program) support vaccination campaigns and biosecurity enforcement to ensure disease control.
   
• Brazil’s geographic position, allowing access to both Northern and Southern Hemisphere markets, drives demand for poultry pharmaceuticals tailored to export destinations.
   
• The country's tropical and subtropical climate presents environmental risks that heighten susceptibility to respiratory and enteric diseases, particularly infectious bronchitis, increasing demand for targeted pharmaceuticals.
   

Saudi Arabia poultry pharmaceuticals market to experience substantial growth in the Middle East and Africa market in 2024.
 

• The Saudi Arabia market is poised for substantial growth due to climatic stress and disease vulnerability in poultry flocks.
   
• Extreme heat and humidity in the region weaken bird immunity, heightening the need for regular preventive vaccination.
   
• With over 85% of poultry breeding stock imported, Saudi Arabia enforces strict vaccination protocols to protect domestic flocks from diseases such as Marek’s disease and avian influenza.
   
• These regulatory requirements and environmental challenges are expected to significantly boost poultry pharmaceutical adoption across the country.
   

Poultry Pharmaceuticals Market Share

The market is characterized by diverse players competing in the industry. The top 5 players such as Boehringer Ingelheim, Ceva Sante Animale, Zoetis, Elanco and Phibro Animal Health account for 75% of the market share in the moderately consolidated global market. These prominent players thrive through a combination of strategic initiatives, investing in research and development, meeting the specific needs of poultry pharmaceuticals, geographical expansion, strategic approaches, and regulatory compliance.
 

Companies are using competitive pricing strategies for biologics, pharmaceuticals and medicated feed additives which are intended to provide a more affordable option, in an effort to increase their market share. Players are also addressing market gaps by launching novel drug therapeutics, that offer significant advantages over conventional treatment plans.
 

Further, leading players in the industry are leveraging a multi-pronged strategic approach including acquisitions, partnerships, R&D investments, to reinforce their competitive positioning and respond to the rising demand for poultry pharmaceuticals globally. In addition to the established global leaders, emerging players are increasingly influencing the market, particularly in regions like Asia-Pacific and Latin America.
 

Poultry Pharmaceuticals Market Companies

Prominent players operating in the poultry pharmaceuticals industry are as mentioned below:

• Avimex
• Boehringer Ingelheim International
• Calier
• Ceva Sante Animale
• Elanco
• Hester Biosciences
• Indovax
• Kemin Industries
• Merck
• Phibro Animal Health
• Vaxxinova (EW Group)
• Vetanco
• Virbac
• Zoetis
   
• Zoetis

Zoetis offer robust poultry pharmaceutical portfolio covering vaccines, and biologics that are supported by advanced research and development approaches with global distribution. The company’s innovative technologies such as Inovoject enable precise, large-scale in-ova vaccination for flock protection.
 

• Ceva Sante Animale

Ceva provides a robust poultry health portfolio with a strong focus on vector vaccines targeting respiratory disease control. Its commitment to customer-centric services, combined with strategic partnerships aimed at reducing antibiotic use, reinforces its position as a sustainability-focused leader in the poultry pharmaceuticals industry.  
 

• Boehringer Ingelheim

Boehringer Ingelheim is one of the key players in the market, offering renowned innovative poultry pharmaceutical such as Vectormune with strong expertise in immune modulating solutions. The company integrates global R&D with targeted regional strategies, offering customized vaccination programs to control complex poultry disease and enhance overall flock productivity.
 

Poultry pharmaceuticals Industry News

• In March 2025, Alembic Pharma signs deal with Amlan International to bring poultry health solutions to India. This collaboration will expand access to advanced feed additives that improve gut health, nutrient absorption, and feed conversion ratio (FCR), ensuring better poultry yields and supporting the industry’s growing demand for high-quality protein.
   
• In February 2021, MSD Animal Health announced the completion of its acquisition of PrognostiX Poultry Limited d/b/a Poultry Sense Ltd. from its founding shareholders. Poultry Sense Ltd. is an innovator in health and environmental monitoring solutions for the poultry industry.
   
• In January 2020, Boehringer Ingelheim’s U.S. Animal Health Business launched a vaccine to protect poultry from three diseases. VAXXITEK HVT+IBD+ND provides a strong immune foundation and optimized protection against Marek’s disease, infectious bursal disease (classic and variant types) and Newcastle disease.
   

The poultry pharmaceuticals market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Species

• Chicken
• Turkey
• Ducks
• Other species  

Market, By Product

• Biologics
  • Vaccines
    • Modified/ attenuated live
    • Inactivated (killed)
    • Other vaccines
  • Other biologics
• Pharmaceuticals
  • Parasiticides
  • Anti-infectives
  • Anti-inflammatory and analgesics
  • Other pharmaceuticals
• Medicated feed additives

Market, By Disease Type

• Newcastle disease
• Infectious bronchitis
• Infectious bursal disease
• Coccidiosis
• Salmonella
• Marek's disease
• Other disease types

Market, By Route of Administration

• Oral
• Injectable
• Topical
• Other routes of administration

Market, By End Use

• Veterinary hospitals and clinics
• Poultry farms
• Retail veterinary pharmacies
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE